Astaxanthin
increases
Adiponectin
Astaxanthin
increases
Adiponectin
7.3
ValidityScore
Valid or Invalid?
-
2018RCT
-
Mashhadi NS, et al. -
«RESULTS: The 8-week administration of AST supplementation increased the serum adiponectin concentration and reduced visceral body fat mass (p<0.01), serum triglyceride and very-low-density lipoprotein cholesterol concentration, and systolic blood pressure (p<0.05). Furthermore, AST significantly reduced the fructosamine concentration (p<0.05) and marginally reduced the plasma glucose concentration (p=0.057).
CONCLUSIONS: We demonstrated that because participants with type 2 diabetes often have hypertriglycemia and uncontrolled glucose metabolism; our findings of dual beneficial effects are clinically valuable. Our results may provide a novel complementary treatment with potential impacts on diabetic complications without adverse effects.» - Organism: Humans
- Minor Magnitude of Effect.
-
-
2010RCT
-
Ito K, Koikeda T, Tada N, Tomono Y, Tsukahara H, Yanai H, Yoshida H -
« Placebo-controlled astaxanthin administration at doses of 0, 6, 12, 18 mg/day for 12 weeks was randomly allocated to 61 non-obese subjects with fasting serum triglyceride of 120-200mg/dl and without diabetes and hypertension, age 25-60 years.»
«In before and after tests, body mass index (BMI) and LDL-cholesterol were unaffected at all doses, however, triglycerides decreased, while HDL-cholesterol increased significantly. Multiple comparison tests showed that 12 and 18 mg/day doses significantly reduced triglyceride, and 6 and 12 mg doses significantly increased HDL-cholesterol. Serum adiponectin was increased by astaxanthin (12 and 18 mg/day), and changes of adiponectin correlated positively with HDL-cholesterol changes independent of age and BMI.» - Dose: 12 and 18 mg/day
- Organism: Humans
- Notable Magnitude of Effect.
-
#Adiponectin / blood*, Adult, Cholesterol, Female, HDL / blood*, Hidekatsu Yanai, Hiroshi Yoshida, Humans, Hyperlipidemias / blood*, Hyperlipidemias / drug therapy, MEDLINE, Male, Middle Aged, NCBI, NIH, NLM, National Center for Biotechnology Information, National Institutes of Health, National Library of Medicine, Non-U.S. Gov', Norio Tada, PubMed Abstract, Randomized Controlled Trial, Research Support, Triglycerides / blood, Xanthophylls / therapeutic use, doi:10.1016/j.atherosclerosis.2009.10.012, pmid:19892350more... -
-
2009
-
Yoshida H, et al. -
«RESULTS: In before and after tests, body mass index (BMI) and LDL-cholesterol were unaffected at all doses, however, triglyceride decreased, while HDL-cholesterol increased significantly. Multiple comparison tests showed that 12 and 18 mg/day doses significantly reduced triglyceride, and 6 and 12 mg doses significantly increased HDL-cholesterol. Serum adiponectin was increased by astaxanthin (12 and 18 mg/day), and changes of adiponectin correlated positively with HDL-cholesterol changes independent of age and BMI.
CONCLUSIONS: This first-ever randomized, placebo-controlled human study suggests that astaxanthin consumption ameliorates triglyceride and HDL-cholesterol in correlation with increased adiponectin in humans.» - Organism: Humans
- Minor Magnitude of Effect.
-
ranked
added it
2 years ago
on May 11, 2020